Free Trial
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel
NASDAQ:OKYO

OKYO Pharma Q2 2026 Earnings Results & Report

OKYO Pharma logo
$1.42 +0.03 (+2.16%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$1.44 +0.02 (+1.41%)
As of 10/9/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma missed analyst earnings expectations in its Q2 2026 results, released January 30, 2026. The company reported EPS of -$2.2750 versus the -$0.07 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

OKYO Pharma EPS Results

Actual EPS
-$2.2750
Consensus EPS
-$0.07
Beat/Miss
Missed by -$2.2050
One Year Ago EPS
N/A

OKYO Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

OKYO Pharma's Q1 2027 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedules

Conference Call Resources

OKYO Pharma Q2 2026 Earnings FAQ

OKYO Pharma (NASDAQ:OKYO) reported earnings of -$2.2750 per share for Q2 2026, missing the consensus estimate of -$0.07. The report was announced on Friday, January 30, 2026.

OKYO Pharma's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for OKYO Pharma on the company's earnings history page.

OKYO Pharma Earnings Headlines

OKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal Pain
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696858/okyo-pharma-begins-phase-3-trial-of-urcosimod-for-neuropathic-corneal-pain.aspx
OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/video/okyo-pharma-begins-phase-3-140915709.html
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug
October 6, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099655?snapi
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375318/0/en/okyo-pharma-announces-first-patients-enrolled-in-phase-3-pivotal-trial-of-urcosimod-for-neuropathic-corneal-pain.html
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 9.7% - Still a Buy?
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081476
See More OKYO Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OKYO Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OKYO Pharma and other key companies, straight to your email.

About OKYO Pharma

OKYO Pharma (NASDAQ:OKYO) Limited (NASDAQ: OKYO) is a clinical-stage biotechnology company developing therapies for diseases driven by inflammation and immune-system dysfunction. The company uses a drug-discovery platform focused on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in pain, inflammation and other disease processes.

OKYO’s lead candidate, OK-101, is being developed as a locally acting treatment for ocular diseases, including dry eye disease and neuropathic corneal pain. The company has also investigated additional potential applications for its GPCR-targeted drug candidates in inflammatory and immunological conditions.

OKYO Pharma was established in the United Kingdom and is listed on the Nasdaq Capital Market. Its research and development activities are focused on advancing internally discovered therapies through clinical development. The company is led by Chief Executive Officer Gary S. Jacob, a biotechnology executive and scientist with experience in GPCR drug discovery.

View OKYO Pharma Profile
Earnings Tools